Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 18.0% in February

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 289,400 shares, a decline of 18.0% from the February 13th total of 353,000 shares. Based on an average daily trading volume, of 263,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. B. Riley restated a "buy" rating and issued a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday.

Eton Pharmaceuticals Price Performance

ETON stock traded down $0.56 during trading on Friday, reaching $14.22. 223,652 shares of the company were exchanged, compared to its average volume of 159,507. The company has a 50-day moving average of $15.58 and a two-hundred day moving average of $11.54. The company has a market capitalization of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $18.41.

Remove Ads

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The business had revenue of $11.65 million during the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. On average, analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. increased its position in Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after purchasing an additional 1,634 shares in the last quarter. XTX Topco Ltd grew its holdings in Eton Pharmaceuticals by 29.6% during the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock worth $195,000 after acquiring an additional 3,351 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $86,000. Parkman Healthcare Partners LLC grew its holdings in Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company's stock worth $1,561,000 after acquiring an additional 7,029 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $133,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.